Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 1/20 | 0.60 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.55 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.55 |
| ▸ | SCD5 | Q86SK9 | 5/20 | 0.54 |
| ▸ | SCD | O00767 | 2/20 | 0.54 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL165005 | 0.90 | SCD (0.55) | PARP14PARP10HSP90AA1HSP90AB1ROCK2 | |
| SCHEMBL166844 | 0.86 | ALDH1A1 (0.65) | ROCK2SCD | |
| SCHEMBL166794 | 0.86 | ROCK2 (0.60) | PARP14PARP10HSP90AA1HSP90AB1ROCK2 | |
| SCHEMBL166963 | 0.85 | RIPK1 (0.54) | PARP14PARP10HSP90AA1HSP90AB1ROCK2 | |
| SCHEMBL8596155 | 0.84 | PARP14 (0.62) | PARP14PARP10HSP90AA1HSP90AB1ROCK2 | |
| SCHEMBL8538915 | 0.82 | HSP90AA1 (0.63) | PARP14PARP10HSP90AA1HSP90AB1ROCK2 | |
| SCHEMBL166512 | 0.81 | POLB (0.57) | ROCK2L3MBTL3 | |
| SCHEMBL167401 | 0.80 | ROCK2 (0.46) | ROCK2L3MBTL3 | |
| SCHEMBL256556 | 0.79 | RIPK1 (0.53) | PARP14PARP10HSP90AA1HSP90AB1ROCK2 | |
| SCHEMBL16565652 | 0.79 | SCD (0.60) | PARP14PARP10HSP90AA1HSP90AB1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611441-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-10 | — | — | EP | disclosed |
| CN-103079562-A | BACE inhibitors for use in the treatment of diabetes | HOFFMANN LA ROCHE | 2013-05-01 | — | — | CN | disclosed |
| WO-2012028563-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012028563-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053200-A1 | BACE 2 INHIBITORS | BACE2, BACE1, PSEN2 | PARP14 2192/4885PARP10 2224/4885HSP90AA1 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.